The Association between Metaplasia and Gastric Malignancy with Helicobacter pylori Infection

Riki Tenggara, Visakha Revana Irawan
Department of Internal Medicine, Faculty of Medicine, Atma Jaya Catholic University of Indonesia, Jakarta

Corresponding author:
Riki Tenggara. Department of Internal Medicine, Faculty of Medicine, Atma Jaya Catholic University of Indonesia. Jl Pluit Raya No. 2 Jakarta Indonesia. Phone: +62-21-6694366; Facsimile: +62-21-6693168. Email: rikitenggara@yahoo.com

ABSTRACT

Background: Helicobacter pylori (H. pylori) infection is the main cause of peptic ulcer disease, gastric mucosa metaplasia, and gastric malignancy. The hypothesis of this study is whether there’s an association between metaplasia and gastric malignancy with H. pylori infection.

Method: We conducted a retrospective study on 1,127 dyspepsia subjects who performed endoscopy between 2001 to 2011 at a hospital in North Jakarta. Data is obtained based on endoscopy and histopathology data. Investigation of H. pylori in this study using histopathology examination.

Results: Of the 1,127 dyspepsia subjects who performed endoscopy and biopsy, there were 130 (11.54%) H. pylori-positive subjects. Gender proportion was composed of 55.37% men and 44.63% women, with median age was 47 years. On the histopathology examination, we obtained 45 metaplasia subjects with median age of 45 years and 7 malignancy subjects with median age of 64 years. Metaplasia was found in 33 of 997 (3.31%) H. pylori-negative subjects and 12 of 130 (9.23%) H. pylori-positive subjects. All gastric malignancy subjects had H. pylori-negative results.

Conclusion: There was an association between metaplasia and H. pylori infection, but no association between gastric malignancy and H. pylori infection.

Keywords: metaplasia, gastric malignancy, H. pylori infection, retrospective study

ABSTRAK

Latar belakang: Infeksi Helicobacter pylori (H. pylori) adalah penyebab utama penyakit ulkus peptikum, metaplasia Mukosa lambung, dan keganasan lambung. Hipotesis studi ini adalah apakah terdapat hubungan antara metaplasia dan keganasan lambung dengan infeksi H. pylori.

Metode: Kami melakukan studi retrospektif terhadap 1.127 subyek dyspepsia yang dilakukan endoskopi antara tahun 2001-2011 di rumah sakit di Jakarta Utara. Data didapatkan berdasarkan data endoskopi dan histopatologi. Pemeriksaan H. pylori pada penelitian ini menggunakan pemeriksaan histopatologi.

Hasil: Dari 1.127 subyek dyspepsia yang dilakukan endoskopi dan biopsi, terdapat 130 (11,54%) subyek positif H. pylori. Proporsi jenis kelamin didapatkan 55,37% laki-laki dan 44,63% perempuan dengan median usia 47 tahun. Pada pemeriksaan histopatologi, kami mendapatkan 45 subyek dengan gambaran metaplasia dengan median usia 45 tahun dan 7 subyek mengalami keganasan lambung dengan median usia 64 tahun. Metaplasia didapatkan pada 33 dari 997 (3,31%) subyek negatif H. pylori dan 12 dari 130 (9,23%) subyek positif H. pylori. Semua subyek keganasan lambung memberikan hasil H. pylori yang negatif.
**Simpulan:** Terdapat hubungan antara metaplasia dengan infeksi H. pylori, tetapi tidak ada hubungan antara keganasan lambung dengan infeksi H. pylori.

**Kata Kunci:** metaplasia, keganasan lambung, infeksi H. pylori, studi retrospektif

**INTRODUCTION**

*H. pylori* is one of the most common infections in human. This infection is associated with a number of important conditions in the upper gastrointestinal tract, such as chronic gastritis, peptic ulcer disease (PUD), and gastric malignancy. The prevalence of *H. pylori* tends to be related to socioeconomic conditions, therefore the infection is more prevalent in developing countries. The prevalence of *H. pylori* in developed countries is generally below than 40% and this number is dominated by adults and elderly. In Asia, the prevalence of *H. pylori* infection ranges from 54% to 76%. Each year, about 990,000 individuals in the world are diagnosed with gastric malignancy, and 738,000 of them die. This causes gastric malignancy is in the fourth position as the most common cancer, and the second position as most common cause of cancer death.

Gastric malignancy usually develops due to mucosal changes from non-atrophic gastritis to atrophic gastritis, intestinal metaplasia and dysplasia, and adenocarcinoma. Atrophic gastritis and intestinal metaplasia may be considered as a pre-neoplastic lesion. *H. pylori* infection is the first step in the presence of gastric carcinogenesis cascade. Several studies hypothesize that treatment of *H. pylori* may prevent the development of intestinal metaplasia into gastric adenocarcinoma. There is no definitive population data suggesting that *H. pylori* eradication can decrease the incidence of gastric adenocarcinoma. The hypothesis of this study is whether there is an association between metaplasia and gastric malignancy with *H. pylori* infection.

**METHOD**

This retrospective study was conducted in hospitals at North Jakarta between 2001-2011. A total of 1,127 subjects, who underwent endoscopy, with complaints of dyspepsia, defined as pain or discomfort centered in the upper abdomen and lasting for one month or more, were included in the study. Subjects with a history of gastrointestinal surgery were excluded. Informed consent is obtained from subjects who will undergo endoscopic examination. All endoscopic examinations are performed by endoscopic expert. Endoscopic findings are evaluated, such as macroscopic changes, i.e. erythema, erosion, mucosal defects, absence of rugae, or bleeding spots.

The data taken are endoscopic and histopathology data from research subjects. In this study, *H. pylori* examination used histopathological examination. The biopsy sample was examined in anatomical pathology department. Data were entered and analyzed using statistical package for social science (SPSS) for windows version 16.0. The analysis was done using Chi-square test to determine the association between metaplasia and gastric malignancy, and *H. pylori* infection. A statistically significant level was defined as p < 0.05.

**RESULTS**

Total of 1,127 of dyspepsia subjects were enrolled in the study and the median age of the subjects was 47 years old. The proportion of gender was 55.37% (n = 624) men and 44.63% (n = 503) women. Out of 1,127 subjects, 130 (11.54%) were positive and 997 (88.46%) were negative for *H. pylori* infection. Table 1 describes the characteristics among subjects enrolled in the study.

| Sex          | Total | *H. pylori*-positive | *H. pylori*-negative |
|--------------|-------|----------------------|---------------------|
|              | n     | n (%)                | n (%)               |
| Men          | 624   | 78 (12.5)            | 546 (87.5)          |
| Women        | 503   | 52 (10.34)           | 451 (89.66)         |
| Age < 40     | 394   | 44 (11.17)           | 350 (88.83)         |
| 40-59        | 436   | 53 (12.16)           | 383 (87.84)         |
| > 60         | 297   | 33 (11.11)           | 264 (88.89)         |
| Total        | 1,127 | 130 (11.54)          | 997 (88.46)         |

A comparison of histologic findings between two groups is explained in Table 2. A significant association was observed between *H. pylori*-positive infection and the intestinal metaplasia findings (p < 0.05). We obtained 45 subjects have metaplasia with a median age of 45 years and 7 subjects have gastric malignancy with a median age of 64 years. Metaplasia was found in 33 of 997 (3.31%) *H. pylori*-negative subjects and 12 of 130 (9.23%) *H. pylori*-positive subjects. All subjects of gastric malignancy were found have negative *H. pylori* infection. We found that there were no association between gastric malignancy and *H. pylori* infection (p > 0.05).
Previous study reported that *H. pylori* infection rates increase with age, i.e. 51.6% at age around 30 years and 70% at age above 60 years.\(^7\) Ohkuma et al explained that the prevalence of intestinal metaplasia increased significantly in elderly (OR = 5.5) with *H. pylori* infection.\(^7\)

Geographical data affect the prevalence of *H. pylori* and incidence of gastric malignancy. *H. pylori* colonization is estimated to increase the risk of gastric malignancy by tenfold.\(^2\) The development of gastric malignancy consists of several stages, i.e. inflammation of gastric mucosa associated with *H. pylori* infection, atrophic gastritis, intestinal metaplasia, dysplasia, and intestinal type gastric malignancy.\(^9\) The histologic developmental mechanisms remain unknown.\(^14\)

Intestinal metaplasia is defined as the replacement of gastric columnar epithelial cells into intestinal morphological cells, which is characterized by goblet cells, Paneth cells, and absorptive cells.\(^8\) Point of no return can occur in the histological cascade of chronic gastritis to adenocarcinoma, where *H. pylori* eradication can’t prevent gastric malignancy occurring in this condition. A meta-analysis of 12 studies conducted on 2,658 patients concluded that *H. pylori* eradication had an impact on improvements in gastric corpus atrophy, but did not have any effect on intestinal metaplasia. However, *H. pylori* elimination is still a promising strategy for reducing the incidence of gastric malignancy.\(^13\) Leung et al concluded that *H. pylori* eradication has a protective effect in progression to a pre-neoplastic gastric lesion in Chinese populations.\(^1\) Study that involved 1,526 Japanese populations provide evidence that *H. pylori* infection significantly increases the risk of gastric malignancy.\(^17\) Uemura et al reported that gastric malignancy can develop in about 3% of subjects infected with *H. pylori*, compared with uninfected subjects.\(^20\) *H. pylori* eradication may significantly reduce the risk of gastric malignancy in infected subjects, with no gastric pre-neoplastic lesions.\(^13,20\) Diagnosis of gastric pre-neoplastic lesions, such as atrophic gastritis and intestinal metaplasia, of endoscopy results are helpful for individuals at high risk of gastric malignancy. Health check-up endoscopy is a well-known screening test for gastric malignancy.\(^9\)

In our study, there was a gastric malignancy of the subjects with a negative *H. pylori* infection. Some studies described about *H. pylori*-negative gastric cancers (HpNGC) cases, and the prevalence was about 0.42-5.4% of the gastric malignancy total incidence.\(^17\) The prevalence of HpNGC is found to be very low in the Japanese population (0.66%), with pathological
characteristics distinct from gastric malignancy in general.\textsuperscript{18} Kato et al reports that a small proportion of patients with gastric malignancy indicates a multifactorial carcinogen without \textit{H. pylori} infection. This indicates that gastric malignancy can still exist without \textit{H. pylori} infection, with an incidence of 2-10.6%.\textsuperscript{19}

Diagnostic criteria for HpNGC vary greatly among case reports, and have not been definitively defined. Etiology of gastric malignancy, in addition to \textit{H. pylori} infection, is usually associated with several factors, such as lifestyle, viral infections, autoimmune diseases, and germline mutations. Nevertheless, the main factor causing HpNGC remains unclear.\textsuperscript{17}

This study also has limitations. The location of endoscopy and severity has not been classified. In additional, patients with metaplasia and \textit{H. pylori}-negative infection have either had a previous \textit{H. pylori} infection or currently have an ongoing infection, even though no bacteria were found in the histologic analyses. The large amount of analytical experience from endoscopic experts can also help increase the rate of detection of intestinal metaplasia in future studies.

CONCLUSION

There was an association between metaplasia and \textit{H. pylori} infection, but no association between gastric malignancy and \textit{H. pylori} infection. Further research with a larger sample or case series that includes subjects with gastric malignancy is needed to provide evidence regarding the association between these two things.

REFERENCES

1. Choy WD, Wong BCY. American College of Gastroenterology Guideline on the Management of \textit{Helicobacter pylori} Infection. Am J Gastroenterol 2007;102:1808-25.
2. Kusters JG, van Vliet AHM, Kuipers EJ. Pathogenesis of \textit{Helicobacter pylori} Infection. Clin Microbiol Rev 2006;19:449-90.
3. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of \textit{Helicobacter pylori} Infection. \textit{Helicobacter} 2014;19:1-5.
4. Karimi P, Ismail F, Anandhasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 2014;23:700-13.
5. Liu KSH, Wong IOL, Leung WK. \textit{Helicobacter pylori} associated gastric intestinal metaplasia: treatment and surveillance. World J Gastroenterol 2016;22:1311-20.
6. Topal D, Goral V, Yilmaz F, Kara IH. The relation of \textit{Helicobacter pylori} with intestinal metaplasia, gastric atrophy, and BCL-2. Turk J Gastroenterol 2004;15:149-55.
7. Ohkuma K, Okada M, Murayama H, Seo M, Maeda K, Kanda M, et al. Association of \textit{Helicobacter pylori} infection with atrophic gastritis and intestinal metaplasia. J Gastroenterol Hepatol 2000;15:1105-12.
8. Kim HJ, Choi BY, Byun TJ, Eun CS, Song KS, Kim YS, et al. The prevalence of atrophic gastritis and intestinal metaplasia according to gender, age, and \textit{Helicobacter pylori} infection in a rural population. J Prev Med Public Health 2008;41:373-9.
9. Joo YE, Park HK, Myung DS, Baik GH, Shin JE, Seo GS, et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia: a nationwide multicenter prospective study in Korea. Gut and Liver 2013;7:303-10.
10. De Martel C, Parsonnet J. \textit{Helicobacter pylori} infection and gender: a meta-analysis of population-based prevalence surveys. Dig Dis Sci 2006;51:2292-301.
11. Asaka M, Sugiyama T, Nobuta A, Kato M, Takeda H, Graham DY. Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. \textit{Helicobacter} 2001;6:294-9.
12. Malfertheiner P, Peitz U. The Interplay between \textit{Helicobacter pylori}, \textit{Gastro-oesophageal Reflux Disease}, and Intestinal Metaplasia. Gut 2005;54:i13-i20.
13. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon ATR, Bazzoli F, et al. Management of \textit{Helicobacter pylori} infection – The Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
14. Serizawa T, Hirata Y, Hayakawa Y, Suzuki N, Sakitani K, Hikiba Y, et al. Gastric metaplasia induced by \textit{Helicobacter pylori} is associated with enhanced SOX9 expression via interleukin-1 signaling. Infect Immun 2016;84:562-72.
15. Sasidharan S, Ghayethry B, Ravichandran M, Latha LY, Lachumy SJ, Leng KM, et al. Prevalence of \textit{Helicobacter pylori} infection among patients referred for endoscopy: gender and ethnic differences in Kerala, Malaysia. Asian Pac J Trop Dis 2012;55-9.
16. Marusic M, Barac KM, Bilic A, Juricic D, Golcic S, Rotkvic PG, et al. Do gender and age influence the frequency of \textit{Helicobacter pylori} infection? Wien Klin Wochenschr 2013;125:714-6.
17. Yamamoto Y, Fujiyaki J, Omae M, Hirasawa T, Igarashi M. \textit{Helicobacter pylori}-negative gastric cancer: characteristics and endoscopic findings. Dig Endosc 2015;27:551-61.
18. Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Hayama K. Low prevalence of \textit{Helicobacter pylori}-negative gastric cancer among Japanese. \textit{Helicobacter} 2011;16:415-9.
19. Kato S, Matsuura K, Tsukada K, Matsuda N, Mizoshita T, Tsukamoto T, et al. \textit{Helicobacter pylori} infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci 2007;98:790-4.
20. Wroblewski LE, Peek RM, Wilson KT. \textit{Helicobacter pylori} and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010;23:713-39.
21. Bayupurnama P, Nurdjanah S. Histopathological pattern of gastric biopsies of \textit{Helicobacter pylori} positive patients in Sardjito General Hospital Yogyakarta. Indones J Gastroenterol Hepatol Dig Endosc 2000;1:2-4.
22. Syam AF. Dyspepsia and \textit{Helicobacter pylori} infection. Indones J Gastroenterol Hepatol Dig Endosc 2013;14:1-2.